Multidrug-Resistant IncA/C Plasmid in Vibrio cholerae from Haiti

To the Editor: The agents of epidemic cholera are Vibrio cholerae toxigenic serogroups O1 and O139. Cholera symptoms include watery diarrhea and severe dehydration, which can rapidly result in death unless rehydration therapy is prompt (1). Antimicrobial agents may reduce the severity and duration of disease (1); commonly used are tetracyclines, fluoroquinolones, macrodides, and trimethoprim/sulfamethoxazole (1). However, V. cholerae resistance to antimicrobial drugs is increasing because of the accumulation of genetic mutations and the acquisition of resistance genes, which are usually transferred on mobile genetic elements such as integrating conjugative elements (ICEs) (2).

As of March 12, 2014, the ongoing cholera outbreak that began in Haiti in October 2010 had caused 700,796 cases and 8,548 deaths (2). To characterize infections, the National Public Health Laboratory in Haiti and the US Centers for Disease Control and Prevention (CDC) collaborated to perform standard microbiological and antimicrobial-drug susceptibility testing on isolates from case-patients. Since October 2010, the National Public Health Laboratory has identified 465 isolates, which were then forwarded to CDC for determination of MICs for 15 antimicrobial agents by broth microdilution (Sensititre; Trek Diagnostics Systems, Cleveland, OH, USA) according to manufacturer’s recommendations (Table). Resistance was defined by the Clinical and Laboratory Standards Institute interpretive standards, when available (3). The typical outbreak strain (2010EL-1786) displayed resistance to streptomycin, sulfisoxazole, trimethoprim/sulfamethoxazole, and nalidixic acid, and decreased susceptibility to ciprofloxacin and chloramphenicol (4). Resistance was caused by mutations in the QRDR regions of the gyrA and parC genes and presence of ICEVchHai1 containing the dfrA1, floR, strAB, and sul2 resistance genes (4).

In April of 2012, the 2 agencies began sentinel laboratory-based surveillance for acute diarrheal disease at 4 hospitals in Haiti (5). As part of this surveillance, fecal specimens were sent to the National Public Health Laboratory for organism isolation, identification, antimicrobial-drug testing, and subsequently to CDC for expanded antimicrobial-drug testing and molecular characterization. One isolate, 2012EL-2176, showed the typical resistance phenotype of the outbreak strain but additional resistance to ampicillin, amoxicillin/clavulanic acid, cefoxitin, ceftriaxone, cefotiofur; the tetracycline MIC was intermediate (Table).

Analysis of this isolate by serotype, pulsed-field gel electrophoresis, multilocus variable number–tandem repeat analysis, and whole-genome sequencing confirmed that the isolate was similar to outbreak isolates (data not shown) (6). PCR and whole-genome sequencing analysis by use of ResFinder (http://www.genomicepidemiology.org/) identified the original outbreak resistance determinants and additional determinants (aac(3)-IIa, blaCMY-2, blaCTX-M-2*, blaTEM-1, dfrA15,
mPHa, sul1, and tetA) (7). Plasmid transfer by electroporation into *Escherichia coli* (DH10B) confirmed that the resistance determinants were plasmid encoded. PCR-based replicon testing identified an IncA/C2 plasmid, and PCR and whole-genome sequencing confirmed that the plasmid encoded a unique set of resistance determinants (aac(3)-IIa, blA_{CMY-2}, blA_{CTX-M-2}, blA_{TEM-1}, dfrA15, mPHa, sul1, and tetA) and a second copy of the resistance genes floR, strAB, and sul2 identical to those located in *ICEVchHai1* (8). Antimicrobial-drug susceptibility testing of the transformant demonstrated transfer of the resistance profile and additional resistance to chloramphenicol, tetracycline, and decreased susceptibility to azithromycin (Table). The lack of association between the presence of the resistance determinants *floR* and *tetA* and the lack of resistance in *V. cholerae* has been observed previously, possibly because of lower gene expression (9). The plasmid was mobilizable by conjugation (conjugation efficiency = 1.3–1.4 × 10^3) when *E. coli* J53 was used as the recipient.

IncA/C plasmids are widespread in *Enterobacteriaceae* and commonly confer multidrug resistance. BLASTn (http://blast.ncbi.nlm.nih.gov/Blast.cgi) comparison of the completed plasmid p2012EL-2176 sequence with the National Center for Biotechnology Information nucleotide collection showed similarities to other IncA/C-bla_{CMY} plasmids; most similarity (total score = 3.009 × 10^5) was to pAR060302, found in an *E. coli* isolate from a dairy calf (10). Most IncA/C-bla_{CMY} plasmids have 3 resistance regions: sul2 region (*floR*-tetA-*strAB*-sul2), cmy-2 insertion region, and Tn21-like region (*aad-aac*). Plasmid p2012EL-2176 contains the sul2 and cmy-2 insertion regions and a putative arr3-dfrA27-aadA16-sul1 resistance gene cassette at the Tn-21 location. This plasmid has additional resistance gene insertions: a putative cassette containing a blA_{TEM1} and *aac(3)-Ila* gene upstream of the sul2 region and insertions of blA_{CTX-M-2}, sul1, and mPHa genes downstream of the arr3-dfrA27-aadA16-sul1 cassette (online Technical Appendix, http://wwwnc.cdc.gov/EID/article/20/11/14-0889-Techapp1.pdf).

Since discovery of isolate 2012EL-2176, sentinel surveillance has not detected increased antimicrobial-drug resistance among *V. cholerae* in Haiti. The ability of IncA/C plasmids to acquire novel resistance cassettes from multiple sources makes it difficult to hypothesize as to the origins of plasmid p2012EL-2176. Although this plasmid was most closely related to a plasmid found in *E. coli*, it was also closely related to plasmids in *Salmonella*, *Klebsiella*, and *Providencia*. *Enterobacteriaceae* are found in the environment and/or in the host gut; therefore, the isolate could have acquired the plasmid in the environment or within the host. The latter scenario would limit the possible spread of this plasmid and could explain its rarity. The original Haiti outbreak isolate has been shown to be poorly naturally transformable, accounting for the lack of acquired chromosomal genes and nearly homologous genomic content among outbreak isolates (6). Therefore, the acquisition of plasmids, and their resistance genes, may represent the major source of future variability among *V. cholerae* involved in the Haiti outbreak.

**Acknowledgments**

We thank Deborah Talkington, Chery Bopp, Nancy Garrett, Maryann Turnsek, Emmanuel Rossignol, Nicole Freeman, PulseNet, and the Health Systems Recovery Team for their contributions to this work.

**Jason P. Folster, Lee Katz, Andre McCullough, Michele B. Parsons, Kristen Knipe, Scott A. Sammons, Jacques Boncy, Cheryl Lea Tarr, and Jean M. Whichard**

Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (J.P. Folster, L. Katz, M.B. Parsons, K. Knipe, S.A. Sammons, C.L. Tarr, J.M. Whichard); International Health Resources Consulting, Atlanta (A. McCullough); and Laboratoire National de Santé Publique, Port-au-Prince, Haiti (J. Boncy)  
DOI: http://dx.doi.org/10.3201/eid2011.140889

---

**Table. Susceptibility, resistance genes, and plasmids associated with Haiti *Vibrio cholerae* outbreak isolates**

<table>
<thead>
<tr>
<th>Isolate</th>
<th>Resistance profiles [MIC mg/L]*</th>
<th>Resistance genes/mutations</th>
<th>Plasmids</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>V. cholerae</em></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2010EL-1786</td>
<td>STR [&gt;64], FIS [≥256], TMP/SXT [&gt;4], CIP ([0.5], NAL [&gt;32]</td>
<td>strAB sul2, dfrA1, floR, gyrA(SB3 idi)parC(S85L)</td>
<td>None</td>
</tr>
<tr>
<td>2012EL-2176</td>
<td>AMP [&gt;32], AMC [&gt;32], CRO [&gt;64], FOX [&gt;32], TIO [&gt;8], CHL ([16], GEN [&gt;8], STR [&gt;64], FIS [≥256], TMP/SXT [&gt;4], TET ([0.5], NAL [&gt;32]</td>
<td>blA_{CMY-2}, blA_{CTX-M-2}, blA_{TEM-1}, dfrA15, floR, aac(3)-Ila, strAB, sul2, dfrA1, dfrA27, tetA, mPHa, gyrA(SB3 idi)parC(S85L)</td>
<td>IncA/C2</td>
</tr>
<tr>
<td><em>Escherichia coli</em> DH10B</td>
<td>AMP [&gt;32], AMC [&gt;32], CRO [&gt;64], FOX [&gt;32], TIO [&gt;8], AZM [≥16], CHL [≥32], GEN [≥8], STR [≥64], FIS [≥0.5], TMP/SXT [≥1], TET [≥0.2]</td>
<td>blA_{CMY-2}, blA_{CTX-M-2}, blA_{TEM-1}, mphA, floR, aac(3)-Ila, strAB, sul2, dfrA27, tetA</td>
<td>IncA/C2</td>
</tr>
</tbody>
</table>

*Drugs tested were AMP, ampicillin; AMC, amoxicillin/clavulanic acid; AZM, azithromycin; CHL, chloramphenicol; CIP, ciprofloxacin; CRO, ceftriaxone; FIS, sulfisoxazole; FOX, cefoxitin; GEN, gentamicin; KAN, kanamycin; NAL, nalidixic acid; STR, streptomycin; TET, tetracycline; TIO, ceftiofur; and TMP/SXT, trimethoprim/sulfamethoxazole. S83 idi, serine-to-isoleucine change at amino acid position 83; S85L, serine-to-leucine change at amino acid position 85. Drugs that yielded intermediate results are followed by (I). Clinical Laboratory Standards Institute break points are not established for AZM. The AZM break points used in this study (>16 mg/L) were established by the National Antimicrobial Resistance Monitoring System and should not be used to predict clinical efficacy.

†*E. coli* DH10B is intrinsically resistant to STR.
Human Co-Infection with Avian and Seasonal Influenza Viruses, China

To the Editor: In April 2013, a case of co-infection with avian-origin influenza A(H7N9) virus and seasonal influenza A(H3N2) virus was reported in Jiangsu Province, China (1). This case raised concern over the possible occurrence of new reassortants with enhanced transmissibility among humans. Because of the nature of the dynamic reassortment of A(H7N9) virus with A(H9N2) virus in the environment and in poultry (2,3), close surveillance for possible new reassortment in human patients with A(H7N9) infection is needed. We report co-infection in 2 patients in Hangzhou, the capital Zhejiang Province, China, in January 2014. The co-infections involved influenza A(H7N9) virus and a seasonal influenza B virus (1), or a seasonal influenza A virus (2) in 2 patients.

Of 60 patients with laboratory-confirmed influenza A(H7N9) infection in Hangzhou in April 2013 and in January–February 2014, testing of pharyngeal swab samples indicated that 2 patients were also positive for seasonal influenza virus. The pharyngeal swab samples were tested by real-time reverse transcription PCR according to protocols provided by the Chinese National Influenza Center. Informed consent for this study was provided by each patient’s spouse.

On January 6, 2014, patient 1 (male, 58 years of age), a resident of Xiaoshan District, had a high fever (39.6°C) and a cough; at a hospital, he received a diagnosis of severe acute interstitial pneumonia. The patient had a history of chronic myelogenous leukemia; his history of exposure to live poultry was not clear. On January 13, infection with influenza A(H7N9) virus was laboratory confirmed; viral RNA from a pharyngeal swab sample collected before oseltamivir treatment was positive for the following: influenza A virus (cycle threshold \(C_t = 26\)), H7 \((C_t = 27)\), N9 \((C_t = 26)\), influenza A(H1N1)pdm09 virus \(H1\) \((C_t = 30)\), and \(N1\) \((C_t = 30)\). The 2 viruses were named A/Hangzhou/10–1/2014(H7N9) and A/Hangzhou/10–2/2014(H1N1)pdm09. The patient received oseltamivir while in the hospital but died on January 18.

On January 5, patient 2 (male, 54 years of age), also from Xiaoshan District, had fever and a cough; at a hospital, he received a diagnosis of severe acute pneumonia. He had a history of aplastic anemia and had been exposed to live poultry 1 week before symptom onset. On January 18, infection with influenza A(H7N9) virus was laboratory confirmed. Viral RNA from a pharyngeal swab sample collected before oseltamivir treatment was positive for the following: influenza A virus \((C_t = 26)\), H7 \((C_t = 23)\), N9 \((C_t = 22)\), influenza A(H1N1)pdm09 virus \(H1\) \((C_t = 30)\), and influenza B virus \(C_t = 22)\). The viruses were named A/Hangzhou/17–1/2014(H7N9) and B/Hangzhou/17–2/2014(H1N1)pdm09. This patient received oseltamivir but died on January 22.

The hemagglutinin (HA) and neuraminidase (NA) sequences of viruses from these 2 patients were determined by Sanger sequencing. The specific primers used are listed in online Technical Appendix Table 1 (http://wwwnc.cdc.gov/EID/article/20/11/14-0897-Techapp1.pdf). The accession numbers of these sequences and the reference sequences for phylogenetic analyses are

References


Address for correspondence: Jason P. Folster, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Atlanta, GA 30329-4027, USA; email: gux8@cdc.gov
Multidrug-Resistant IncA/C Plasmid in *Vibrio cholerae* from Haiti

Technical Appendix

---

Technical Appendix Figure. Comparative analysis of plasmid p2012EL-2176 to plasmid pAR060302. The genome was sequenced by using NexteraXT library kits, paired-end, 150-bp reads using a MiSeq (Illumina, San Diego, CA, USA) (GenBank accession nos. CP007634 and CP007635) and on 4 SMRT cells on the Pacific Biosciences RS (Pacific Biosciences, Menlo Park, CA, USA) and assembled with the HGAP1 protocol (P_PreAssembler for error correction, Celera Assembler for assembly of corrected reads). A 35× long-read cutoff (8,855 bp) was used in the P_PreAssembler, and the longest (15.3×) of the corrected reads were assembled by Celera. The assembly yielded 1 plasmid contig (GenBank accession
no. CP007636). A BLAST comparison was performed by using BLASTN with a cutoff value of 70% identity and pAR060302 as the reference sequence. The green circle shows the regions of p2012EL-2176 with identity to pAR060302. The blue inserts show regions of p2012EL-2176 containing antimicrobial-drug resistance (AR) genes. The circular plot was generated by using BLAST Ring Image Generator (BRIG) software (1).

Additional methods:

The conjugation experiment used *V. cholerae* 2012EL-2176 as the donor and *E. coli* J53 (sodium azide R) as the recipient (2).

The 3 resistance regions on IncA/C-cmy plasmids are described in this publication (3).

References

